Fig. 1: Outcome of 318 patients receiving donor lymphocyte infusion in complete hematological remission.

NRM non-relapse mortality, CRI cumulative relapse incidence, LFS leukemia-free survival, OS overall survival. DLI was given as prophylaxis (red curves), as preemptive therapy for minimal residual disease (MRD) or molecular relapse (blue curves), or as preemptive therapy for mixed donor chimerism (green curves).